Extended aromatic furan amidino derivatives as anti-Pneumocystis carinii agents. 1998

K T Hopkins, and W D Wilson, and B C Bender, and D R McCurdy, and J E Hall, and R R Tidwell, and A Kumar, and M Bajic, and D W Boykin
Department of Chemistry and Center for Biotechnology and Drug Design, Georgia State University, Atlanta, Georgia 30303-3083, USA.

The syntheses of nine new derivatives of 2, 5-bis[4-(N-alkylamidino)phenyl]furans with extended aromatic systems are reported. The interaction of these dicationic furans with poly(dA)poly(dT) and with the duplex oligomers d(CGCGAATTCGCG)2 and d(GCGAATTCGC)2 was determined by Tm measurement, and the effectiveness of these compounds against the immunosuppressed rat model of Pneumocystis carinii was evaluated. At a screening dose of 10 micromol/kg, 4 of the 12 amidino furans described here are more active than the parent compound 1. In general, extension of the aromatic system in the absence of a substitution of the amidino nitrogens resulted in higher affinity for DNA than the parent compound as judged by the larger DeltaTm values and suggests enhanced van der Waals interactions in the amidino furan-DNA complex. Three of the compounds, 3, 5, and 11, yield cysts counts of less than 0.1% of control when administered at a dosage of 10 micromol/kg. Compound 3, which does not have an extended aromatic system, is the most active derivative. Although a direct correlation between anti-P. carinii activity and DNA binding affinity was not observed, all compounds which have significant activity have large DeltaTm values.

UI MeSH Term Description Entries
D007165 Immunosuppression Therapy Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs. Antirejection Therapy,Immunosuppression,Immunosuppressive Therapy,Anti-Rejection Therapy,Therapy, Anti-Rejection,Therapy, Antirejection,Anti Rejection Therapy,Anti-Rejection Therapies,Antirejection Therapies,Immunosuppression Therapies,Immunosuppressions,Immunosuppressive Therapies,Therapies, Immunosuppression,Therapies, Immunosuppressive,Therapy, Immunosuppression,Therapy, Immunosuppressive
D009838 Oligodeoxyribonucleotides A group of deoxyribonucleotides (up to 12) in which the phosphate residues of each deoxyribonucleotide act as bridges in forming diester linkages between the deoxyribose moieties. Oligodeoxynucleotide,Oligodeoxyribonucleotide,Oligodeoxynucleotides
D011020 Pneumonia, Pneumocystis A pulmonary disease in humans occurring in immunodeficient or malnourished patients or infants, characterized by DYSPNEA, tachypnea, and HYPOXEMIA. Pneumocystis pneumonia is a frequently seen opportunistic infection in AIDS. It is caused by the fungus PNEUMOCYSTIS JIROVECII. The disease is also found in other MAMMALS where it is caused by related species of Pneumocystis. P carinii Pneumonia,P. carinii Pneumonia,P. jirovecii Pneumonia,PCP Pneumonia,Pneumocystis Pneumonia,Pneumocystosis,Pneumonia, Interstitial Plasma Cell,PCP Infection,Pneumocystis carinii Pneumonia,Pneumocystis jirovecii Pneumonia,Pneumonia, Pneumocystis carinii,Infection, PCP,P carinii Pneumonias,P. carinii Pneumonias,P. jirovecii Pneumonias,PCP Infections,PCP Pneumonias,Pneumocystis Pneumonias,Pneumocystoses,Pneumonia, P carinii,Pneumonia, P. carinii,Pneumonia, P. jirovecii,Pneumonia, PCP,Pneumonia, Pneumocystis jirovecii,Pneumonias, PCP
D011067 Poly dA-dT Polydeoxyribonucleotides made up of deoxyadenine nucleotides and thymine nucleotides. Present in DNA preparations isolated from crab species. Synthetic preparations have been used extensively in the study of DNA. Poly(Deoxyadenylate-Thymidylate),Polydeoxyadenine Nucleotides-Polythymine Nucleotides,Poly dA dT,Poly(dA-dT),d(A(5)T(5))2,Nucleotides, Polydeoxyadenine Nucleotides-Polythymine,Nucleotides-Polythymine Nucleotides, Polydeoxyadenine,Polydeoxyadenine Nucleotides Polythymine Nucleotides,dA dT, Poly,dA-dT, Poly,dT, Poly dA
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D005663 Furans Compounds with a 5-membered ring of four carbons and an oxygen. They are aromatic heterocycles. The reduced form is tetrahydrofuran. Tetrahydrofurans
D000578 Amidines Derivatives of oxoacids RnE(
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000935 Antifungal Agents Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. Anti-Fungal Agents,Antifungal Agent,Fungicides, Therapeutic,Antibiotics, Antifungal,Therapeutic Fungicides,Agent, Antifungal,Anti Fungal Agents,Antifungal Antibiotics

Related Publications

K T Hopkins, and W D Wilson, and B C Bender, and D R McCurdy, and J E Hall, and R R Tidwell, and A Kumar, and M Bajic, and D W Boykin
June 1999, Journal of medicinal chemistry,
K T Hopkins, and W D Wilson, and B C Bender, and D R McCurdy, and J E Hall, and R R Tidwell, and A Kumar, and M Bajic, and D W Boykin
March 1995, Journal of medicinal chemistry,
K T Hopkins, and W D Wilson, and B C Bender, and D R McCurdy, and J E Hall, and R R Tidwell, and A Kumar, and M Bajic, and D W Boykin
January 2013, Journal of biomolecular structure & dynamics,
K T Hopkins, and W D Wilson, and B C Bender, and D R McCurdy, and J E Hall, and R R Tidwell, and A Kumar, and M Bajic, and D W Boykin
December 1994, Journal of medicinal chemistry,
K T Hopkins, and W D Wilson, and B C Bender, and D R McCurdy, and J E Hall, and R R Tidwell, and A Kumar, and M Bajic, and D W Boykin
January 1998, Journal of medicinal chemistry,
K T Hopkins, and W D Wilson, and B C Bender, and D R McCurdy, and J E Hall, and R R Tidwell, and A Kumar, and M Bajic, and D W Boykin
May 1994, Antimicrobial agents and chemotherapy,
K T Hopkins, and W D Wilson, and B C Bender, and D R McCurdy, and J E Hall, and R R Tidwell, and A Kumar, and M Bajic, and D W Boykin
October 2001, Bioorganic & medicinal chemistry letters,
K T Hopkins, and W D Wilson, and B C Bender, and D R McCurdy, and J E Hall, and R R Tidwell, and A Kumar, and M Bajic, and D W Boykin
November 1983, Antimicrobial agents and chemotherapy,
K T Hopkins, and W D Wilson, and B C Bender, and D R McCurdy, and J E Hall, and R R Tidwell, and A Kumar, and M Bajic, and D W Boykin
February 1997, Antimicrobial agents and chemotherapy,
K T Hopkins, and W D Wilson, and B C Bender, and D R McCurdy, and J E Hall, and R R Tidwell, and A Kumar, and M Bajic, and D W Boykin
July 1948, Journal of the American Chemical Society,
Copied contents to your clipboard!